CEP43: A promising drug target and biomarker for cancer treatment

Target Name: CEP43

NCBI ID: G11116

CEP43

CEP43: A promising drug target and biomarker for cancer treatment

Abstract:

Centrosomal protein 43 (CEP43) is a protein that plays a crucial role in the proper functioning of mitotic spindles. Its dysfunction has been implicated in various types of cancer, including leukemia, neuroblastoma, and ovarian cancer. The aim of this article is to review the current research on CEP43, its functions, and potential as a drug target or biomarker.

Introduction:

Mitosis is the process of cell division that leads to the development of cancer. The mitotic spindle is a complex structure that plays a vital role in regulating the separation of chromosomes during cell division. CEP43 is a protein that is expressed in various tissues and is involved in the formation and maintenance of the mitotic spindle.

Dysfunction of CEP43:

Several studies have shown that CEP43 is often aberrantly expressed or dysfunctional in various types of cancer. For example, it has been found that CEP43 is overexpressed in many types of cancer, including breast, ovarian, and prostate cancer. Additionally, some studies have shown that CEP43 is involved in the regulation of cell cycle progression, which is a critical step in the development of cancer.

As a drug target, CEP43 can be targeted with small molecules or antibodies that can inhibit its functions. For instance, a small molecule inhibitor, called 1-fluoro-2-deoxy-guanosine (FGDG), has been shown to inhibit CEP43-mediated spindle formation in various cell lines. Similarly, an antibody against CEP43 has been shown to reduce the formation of mitotic spindles in human cancer cell lines.

As a biomarker, CEP43 can be used as a target for cancer diagnosis and treatment. For instance, some studies have shown that the level of CEP43 is significantly increased in the blood and urine of patients with various types of cancer, making it a potential biomarker for cancer diagnosis. Additionally, the formation of mitotic spindles is a critical step in the development of cancer, so any drug that can inhibit CEP43-mediated spindle formation could be an effective cancer treatment.

Conclusion:

In conclusion, CEP43 is a protein that is involved in the formation and maintenance of the mitotic spindle. Its dysfunction has been implicated in various types of cancer. As a drug target, CEP43 can be targeted with small molecules or antibodies that can inhibit its functions. As a biomarker, CEP43 can be used as a target for cancer diagnosis and treatment. Further research is needed to fully understand the role of CEP43 in cancer biology and to develop effective treatments.

Protein Name: Centrosomal Protein 43

Functions: Required for anchoring microtubules to the centrosomes (PubMed:16314388, PubMed:28659385). Required for ciliation (PubMed:28625565, PubMed:28659385)

The "CEP43 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEP43 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets